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                                  INTRODUCTION 
 
Pulmonary hypertension 
Pulmonary hypertension  is an increase in blood pressure in the 
pulmonary artery, pulmonary vein, or pulmonary capillaries leading to 
shortness of breath, dizziness, fainting, and other symptoms, all of which are 
exacerbated by exertion. It was first identified by Dr. Ernst Von Romberg in 
1891 according to the most recent classification, it can be one of five 
different types: arterial, venous, hypoxic, thromboembolic or miscellaneous.  
Signs and symptoms 
Common symptoms are shortness of breath, fatigue, non-productive 
cough, angina pectoris, fainting or syncope, peripheral edema and rarely 
hemoptysis .Pulmonary arterial hypertension (PAH) typically does not 
present with orthopnea or paroxysmal nocturnal dyspnea, while pulmonary 
venous hypertension typically does. 
Diagnosis 
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Because pulmonary hypertension can be of five major types, a series 
of tests must be performed to distinguish pulmonary arterial hypertension 
from venous, hypoxic, thomboembolic, or miscellaneous varieties. 
A physical examination is performed to look for typical signs of 
pulmonary hypertension. These include widely split S2, a loud P2, 
parasternal heave, possible S3 or third heart sound, and pulmonary 
regurgitation. Other signs include an elevated jugular venous pressure, 
peripheral edema ,ascites, hepatojugular reflux, and clubbing. 
Further procedures are required to confirm the presence of pulmonary 
hypertension and exclude other possible diagnoses. These generally include 
pulmonary function tests, blood tests to exclude HIV, autoimmune diseases, 
and liver disease, electrocardiography (ECG), arterial blood gas 
measurements, X-rays of the chest (followed by high-resolution CT 
scanning if interstitial lung disease is suspected), and ventilation-perfusion 
or V/Q scanning to exclude chronic thromboembolic pulmonary 
hypertension.  Clinical improvement is often measured by a "six-minute 
walk test", i.e. the distance a patient can walk in six minutes. . Blood BNP 
level is also being used now to follow progress of patients with pulmonary 
hypertension. 
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Diagnosis of PAH requires the presence of pulmonary hypertension 
with two other conditions. Pulmonary artery occlusion pressure (PAOP or 
PCWP) must be less than 15 mm Hg (2000 Pa) and pulmonary vascular 
resistance (PVR) must be greater than 3 Wood units (240 dyn•s•cm-5 or 2.4 
mN•s•cm-5). 
Although pulmonary arterial pressure can be estimated on the basis of 
echocardiography, pressure measurements with a Swan-Ganz catheter 
provides the most definite assessment. 
Normal pulmonary arterial pressure in a person living at sea level has 
a mean value of 12–16 mm Hg . Pulmonary hypertension is present when 
mean pulmonary artery pressure exceeds 25 mm Hg (3300 Pa) at rest or 30 
mm Hg (4000 Pa) with exercise. 
Mean pulmonary artery pressure (mPAP) should not be confused with 
systolic pulmonary artery pressure (sPAP), which is often reported on 
echocardiogram reports. A systolic pressure of 40 mm Hg typically implies a 
mean pressure more than 25 mm Hg. Roughly, mPAP = 0.61•sPAP + 2. 
 18
Causes and classification 
The Venice 2003 Revised Classification system can be summarized as 
follows 
        WHO Group I - Pulmonary arterial hypertension    
o Idiopathic (IPAH)  
o Familial (FPAH)  
o Associated with other diseases (APAH): collagen vascular 
disease (e.g. scleroderma), congenital shunts between the 
systemic and pulmonary circulation, portal hypertension, HIV 
infection, drugs, toxins, or other diseases or disorders  
o Associated with venous or capillary disease  
• WHO Group II - Pulmonary hypertension associated with left heart 
disease  
o Atrial or ventricular disease  
o Valvular disease (e.g. mitral stenosis)  
• WHO Group III - Pulmonary hypertension associated with lung 
diseases and/or hypoxemia  
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o Chronic obstructive pulmonary disease (COPD), interstitial 
lung disease (ILD)  
o Sleep-disordered breathing, alveolar hypoventilation  
o Chronic exposure to high altitude  
o Developmental lung abnormalities  
• WHO Group IV - Pulmonary hypertension due to chronic thrombotic 
and/or embolic disease  
o Pulmonary embolism in the proximal or distal pulmonary 
arteries  
o Embolization of other matter, such as tumor cells or parasites  
• WHO Group V - Miscellaneous  
 
Pathogenesis 
Whatever the initial cause, pulmonary arterial hypertension (WHO 
Group I) involves the vasoconstriction  of blood vessels connected to and 
within the lungs.. Over time, the affected blood vessels become both stiffer 
and thicker, in a process known as fibrosis. This further increases the blood 
pressure within the lungs and impairs their blood flow. In addition, the 
increased workload of the heart causes thickening and enlargement of the 
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right ventricle, making the heart less able to pump blood through the lungs, 
causing right heart failure. As the blood flowing through the lungs decreases, 
the left side of the heart receives less blood. This blood may also carry less 
oxygen than normal. Therefore it becomes harder and harder for the left side 
of the heart to pump to supply sufficient oxygen to the rest of the body, 
especially during physical activity. 
Pathogenesis in pulmonary venous hypertension (WHO Group II) is 
completely different. There is no obstruction to blood flow in the lungs. 
Instead, the left heart fails to pumps blood efficiently, leading to pooling of 
blood in the lungs. This causes pulmonary edema and pleural effusions. 
In hypoxic pulmonary hypertension (WHO Group III), the low levels 
of oxygen are thought to cause vasoconstriction or tightening of pulmonary 
arteries. This leads to a similar pathophysiology as pulmonary arterial 
hypertension. 
In chronic thromboembolic pulmonary hypertension (WHO Group 
IV), the blood vessels are blocked or narrowed with blood clots. Again, this 
leads to a similar pathophysiology as pulmonary arterial hypertension. 
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Epidemiology 
IPAH is a rare disease with an incidence of about 2-3 per million per 
year and a prevalence of about 15 per million. Adult females are almost 
three times as likely to present with IPAH than adult males. The presentation 
of IPAH within children is more evenly split along gender lines. 
Other forms of PAH are far more common. In scleroderma the 
incidence has been estimated to be 6 to 60% of all patients, in rheumatoid 
arthritis up to 21%, in systemic lupus erythematosus 4 to 14%, in portal 
hypertension between 2 to 5%, in HIV about 0.5%, and in sickle cell disease 
ranging from 20 to 40%. 
Diet pills such as Fen-Phen produced an annual incidence of 25-50 
per million per year. 
Pulmonary venous hypertension is exceedingly common, since it 
occurs in most patients symptomatic with congestive heart failure. 
Up to 4% of people who suffer a pulmonary embolism go on to 
develop chronic thromboembolic disease including pulmonary hypertension. 
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Only about 1.1% of patients with COPD develop pulmonary 
hypertension with no other disease to explain the high pressure. Sleep apnea 
is usually associated with only very mild pulmonary hypertension, typically 
below the level of detection. On the other hand Pickwickian syndrome 
(obesity-hypoventilation syndrome) is very commonly associated with right 
heart failure due to pulmonary hypertension. 
 
Treatment 
Treatment is determined by whether the PH is arterial, venous, 
hypoxic, thromboembolic, or miscellaneous. Since pulmonary venous 
hypertension is synonymous with congestive heart failure, the treatment is to 
optimize left ventricular function by the use of diuretics, beta blockers, ACE 
inhibitors, etc., or to repair/replace the mitral valve or aortic valve. 
In PAH, lifestyle changes, digoxin, diuretics, oral anticoagulants, and 
oxygen therapy are considered conventional therapy, but have never been 
proven to be beneficial in a randomized, prospective manner. 
High dose calcium channel blockers are useful in only 5% of IPAH 
patients who are vasoreactive by Swan-Ganz catheter. The criteria for 
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vasoreactivity have changed. Only those patients whose mean pulmonary 
artery pressure falls by more than 10 mm Hg to less than 40 mm Hg with an 
unchanged or increased cardiac output when challenged with adenosine, 
epoprostenol, or nitric oxide are considered vasoreactive. Of these, only half 
of the patients are responsive to calcium channel blockers in the long term. 
 
 Vasoactive substances 
Many pathways are involved in the abnormal proliferation and 
contraction of the smooth muscle cells of the pulmonary arteries in patients 
with pulmonary arterial hypertension. Three of these pathways are important 
since they have been targeted with drugs — endothelin receptor antagonists, 
phosphodiesterase type 5 inhibitors, and prostacyclin derivatives. 
 
Prostaglandins 
Prostacyclin (prostaglandin I2) is commonly considered the most 
effective treatment for PAH. Epoprostenol (synthetic prostacyclin, marketed 
as Flolan) is given via continuous infusion that requires a semi-permanent 
central venous catheter.. Other prostanoids include. Treprostinil 
(Remodulin) can be given intravenously or subcutaneously, but the 
subcutaneous form can be very painful.  Iloprost  is the only inhaled form of 
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prostacyclin approved for use in the US and Europe.  Oral and inhaled forms 
of Remodulin are under development. Beraprost is an oral prostanoid 
available in Japan and South Korea. 
 
Endothelin receptor antagonists.  
The dual (ETA and ETB) endothelin receptor antagonist bosentan , 
Sitaxentan, ambrisentan are selective endothelin receptor antagonist that 
blocks only the action of ETA, Another dual/nonselective endothelin 
antagonist, Actelion-1,  will enter clinical trials in 2008. 
 
Phosphodiesterase type 5 inhibitors 
Sildenafil, a selective inhibitor of cGMP specific phosphodiesterase 
type 5 (PDE5), was approved for the treatment of PAH in 2005. It is 
marketed for PAH as Revatio. 
 
Surgical 
Atrial septostomy is a surgical procedure that creates a 
communication between the right and left atria. It relieves pressure on the 
right side of the heart, but at the cost of lower oxygen levels in blood 
(hypoxia). It is best performed in experienced centers. 
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Lung transplantation cures pulmonary arterial hypertension, but leaves 
the patient with the complications of transplantation, and a post-surgical 
median survival of just over five years.Pulmonary thromboendarterectomy 
(PTE) is a surgical procedure that is used for chronic thromboembolic 
pulmonary hypertension. It is the surgical removal of an organized thrombus 
(clot) along with the lining of the pulmonary artery; it is a very difficult, 
major procedure that is currently performed in a few select centers. Case 
series show remarkable success in most patients. 
Treatment for hypoxic and miscellaneous varieties of pulmonary 
hypertension have not been established.. 
Monitoring 
Patients are normally monitored through commonly available tests such as: 
• pulse oximetry,  
• arterial blood gas tests,  
• chest X-rays,  
• serial ECG tests,  
• serial echocardiography, and  
• spirometry or more advanced lung function studies.  
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AIM OF THE STUDY 
 
1) To differentiate primary PHT from secondary PHT with the use of  
MPI [Myocardial Performance Index] [TEI INDEX ] 
2) To study the effects of primary PHT and secondary PHT on right  
ventricular function. 
3) To study the effects of primary PHT and secondary PHT on left           
ventricular function. 
4) To study the effects of primary PHT and secondary PHT on mPAP          
[mean pulmonary artey pressure ]. 
5) To study the effects of primary PHT and secondary PHT on PCWP           
[pulmonary capillary wedge pressure ]. 
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REVIEW OF LITERATURE 
 
 
HISTORY  
Presenting symptoms are effort-related. With the onset of right 
ventricular failure, lower extremity edema from venous congestion is 
characteristic. Angina is also a common symptom, generally representing 
more advanced disease. As the cardiac output becomes fixed and eventually 
falls, patients may have episodes of syncope or near-syncope. Patients with 
pulmonary hypertension related to left ventricular diastolic dysfunction will 
characteristically have orthopnea and paroxysmal nocturnal dyspnea. 
Patients with underlying lung disease may also report episodes of coughing. 
Hemoptysis is relatively uncommon in patients with pulmonary 
hypertension and may be associated with underlying thromboembolism and 
pulmonary infarction. Some patients with advanced mitral stenosis also 
present with hemoptysis. 
 
PHYSICAL EXAMINATION  
Large a wave in the jugular venous pulse, a low-volume carotid 
arterial pulse with a normal upstroke, a left parasternal (right ventricular) 
heave, a systolic pulsation produced by a dilated, tense pulmonary artery in 
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the second left interspace, an ejection click and flow murmur in the same 
area, a closely split second heart sound with a loud pulmonic component, 
and a fourth heart sound of right ventricular origin. Late in the course, signs 
of right ventricular failure (e.g., hepatomegaly, peripheral edema, and 
ascites) may be present. Patients with severe pulmonary hypertension may 
also have prominent v waves in the jugular venous pulse as a result of 
tricuspid regurgitation, a third heart sound of right ventricular origin, a high-
pitched early diastolic murmur of pulmonic regurgitation, and a holosystolic 
murmur of tricuspid regurgitation. Tricuspid regurgitation is a reflection of 
right ventricular dilation. Cyanosis is a late finding. Uncommonly, the left 
laryngeal nerve becomes paralyzed as a consequence of compression by a 
dilated pulmonary artery (Ortner syndrome). 
CONCOMITANT DISEASE.  
Patients with scleroderma typically report Raynaud's phenomenon, 
dysphagia, sclerodactyly, and nonspecific arthritic symptoms. Patients with 
portal hypertension usually give a history of underlying chronic liver disease 
and may present with ascites that can be from the liver disease, right heart 
failure, or both. Many patients with congenital heart disease have a known 
history, but atrial septal defects in adults are frequently missed and patients 
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may have symptoms manifest only later in life. These patients often have 
marked cyanosis that worsens with exercise. Patients with pulmonary 
venous hypertension, or pulmonary hypertension associated with lung 
disease, can also have extreme levels of hypoxemia. In patients with chronic 
obstructive pulmonary disease (COPD), the clinical signs are often obscured 
by hyperinflation of the chest. The jugular venous pressure may also be 
difficult to assess in patients with COPD because of large swings in 
intrathoracic pressure. 
DIAGNOSTIC TESTS  
 
Laboratory tests.  
If chronic arterial oxygen desaturation exists, polycythemia should be 
present. A number of investigators have reported hypercoagulable states, 
abnormal platelet function, defects in fibrinolysis, and other abnormalities of 
coagulation in patients with PAH. Abnormal liver function test results can 
indicate right ventricular failure, with resultant systemic venous 
hypertension. 
Brain natriuretic peptide (BNP) levels are elevated in patients with 
pulmonary hypertension and correlate positively with the pulmonary artery 
pressure.  
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Uric acid levels are elevated in patients with pulmonary hypertension 
and correlate with hemodynamics. . 
 There is an increased incidence of thyroid disease in patients with 
PAH, which can mimic the symptoms of right ventricular (RV) failure.. 
Chest radiography.  
Radiographic examination of the chest in patients with pulmonary 
hypertension shows enlargement of the main pulmonary artery and its major 
branches, with marked tapering of peripheral arteries. The right ventricle and 
atrium may also be enlarged. Dilation of the right ventricle gives the heart a 
globular appearance, but right ventricular hypertrophy or dilation is not 
easily discernible on a plain chest radiograph. Encroachment of the 
retrosternal air space on the lateral film may be a helpful sign to confirm that 
the enlarged silhouette is a result of right ventricular dilation. The lung fields 
should be clear, and often appear darkened from the relative oligemia caused 
by a low cardiac output. 
Electrocardiography .  
The electrocardiogram in patients with PAH usually exhibits right 
atrial and right ventricular enlargement. T wave inversion, representing the 
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repolarization abnormalities associated with right ventricular hypertrophy 
(RVH) are usually seen in the anterior precordial leads and may be mistaken 
for anteroseptal ischemia.  
 
Echocardiography .  
Echocardiography usually demonstrates enlargement of the right 
atrium and ventricle, normal or small left ventricular dimensions, and a 
thickened interventri-cular septumAbnormal septal motion as a result of the 
right ventricular pressure overload is characteristic.. 
Doppler echocardiographic estimates of right ventricular systolic 
pressures can be obtained by measuring the velocity of the tricuspid 
regurgitant jet and using the Bernoulli formula  . Although Doppler 
measurements correlate with right ventricular systolic pressure, they are 
relatively imprecise (±20 mm Hg) and are not a substitute for catheterization 
if a correct measurement of pulmonary pressure is needed. Doppler 
echocardiography has also demonstrated that left ventricular diastolic 
dysfunction develops from the pulmonary hypertensive state, with marked 
dependence on atrial contraction for ventricular filling. 
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Radionuclide Ventriculography.  
Radionuclide ventriculography can provide useful information 
regarding right ventricular function, provided that adequate separation of the 
cardiac chambers can be accomplished. Because radioactive counts are 
proportional to volume, variations in the geometric configuration of the 
ventricles are less important. Although pulmonary artery pressure cannot be 
estimated with this technique, there is an inverse relationship between 
pulmonary artery pressure and right ventricular ejection fraction. 
 
Pulmonary Function Tests.  
 A significant obstructive pattern is not characteristic and suggests 
obstructive airways disease. In patients with PAH, the diffusing capacity for 
carbon monoxide (DLCO) is reduced to approximately 60 to 80 percent of 
predicted; there is no clear correlation between severity of the disease and 
the DLCO. The presence of arterial hypoxemia is caused by ventilation-
perfusion mismatch and/or reduced mixed venous oxygen saturations 
resulting from low cardiac output. . 
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Approximately 20 percent of patients with systemic sclerosis have an 
isolated reduction in DLCO, which, when severe (less than 55 percent of 
predicted), can be associated with the development of PAH. In patients with 
limited systemic sclerosis, a fall in DLCO in the presence of normal lung 
volumes often precedes the onset of PAH. 
Lung Scintigraphy.  
A perfusion lung scan is an important test in making the correct 
diagnosis of pulmonary hypertension. Patients with PAH may reveal a 
relatively normal perfusion pattern or diffuse, patchy, perfusion 
abnormalities. A perfusion lung scan will reliably distinguish patients with 
PAH from those who have pulmonary hypertension secondary to chronic 
pulmonary thromboembolism. 
Computed Tomography   
 Spiral chest CT scans have been used successfully in diagnosing 
chronic thromboembolic pulmonary hypertension. High-resolution CT is the 
best test by which to diagnose interstitial lung disease. It has a high degree 
of specificity, but its sensitivity is low. However, patients with PAH without 
coexisting lung disease should have normal lung parenchyma. Thus, 
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although CT tends to underrepresent the extent of the disease, the presence 
of any interstitial abnormality would suggest that interstitial lung disease is 
underlying the pulmonary hypertension. A high-resolution CT scan of the 
chest is also an accurate means of detecting emphysema. 
Pulmonary Angiography.  
Pulmonary angiography establishes the correct diagnosis in patients 
with pulmonary hypertension in whom a perfusion lung scan suggests 
segmental or lobar defects. Although pulmonary angiography carries an 
increased risk in patients with pulmonary hypertension, it can be performed 
safely if adequate precautions are taken. Maintenance of adequate 
oxygenation by the administration of supplemental oxygen and the 
avoidance of vasovagal reactions, and rapid treatment of those that occur 
with intravenous atropine, should reduce the associated risk in this patient 
group. Continuous arterial pressure monitoring is advised, and nonionic 
contrast agents appear to be better tolerated. 
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CLUES FOR INTERPRETATION OF DIAGNOSTIC TESTS FOR 
PULMONARY HYPERTENSION 
 
Test Notable Findings 
Chest x-ray Enlargement of central pulmonary arteries reflects 
level of PA pressure and duration. 
Electrocardiography Right axis deviation and precordial T wave 
abnormalities are early signs. 
Pulmonary function 
tests 
Elevated pulmonary artery pressure causes 
restrictive physiology. 
Perfusion lung scan Nonsegmental perfusion abnormalities can occur 
from severe pulmonary vascular disease. 
Chest computed 
tomography scan 
Minor interstitial changes may reflect diffuse 
disease; mosaic perfusion pattern indicates 
thromboembolism and/or left heart failure. 
Echocardiography Right ventricular enlargement will parallel the 
severity of the pulmonary hypertension. 
Contrast 
echocardiography 
Minor right to left shunting rarely produces 
hypoxemia. 
Doppler 
echocardiography 
This is too unreliable for following serial 
measurements to monitor therapy. 
Exercise testing This is very helpful to assess the efficacy of 
therapy. Severe exercise-induced hypoxemia 
should cause consideration of a right-to-left shunt. 
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CARDIAC CATHETERIZATION.  
In addition to confirming the diagnosis and allowing the exclusion of 
other causes, cardiac catheterization also establishes the severity of disease 
and allows an assessment of prognosis. By definition, patients with PAH 
should have a low or normal pulmonary capillary wedge pressure. Because 
this is a critical measurement in distinguishing a patient with PAH from one 
with pulmonary venous hypertension, several quality measures must be 
established in the catheterization laboratory to ensure that correct values are 
obtained. 
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HEMODYNAMIC ASSESSMENT OF VASODILATORS IN 
PULMONARY HYPERTENSION 
Parameter 
Measured 
Desired Acute 
Changes Comments 
Mean pulmonary 
artery pressure 
(PAP) 
>10-mm Hg 
decrease; ideally, 
mean PAP below 30 
mm Hg 
Must not be associated significant 
fall in systemic blood pressure 
Pulmonary 
vascular resistance 
(PVR) 
>33% decrease; 
ideally, PVR below 
6 units 
Cardiac output unchanged or 
increased 
Pulmonary 
capillary wedge 
pressure 
No change Increase in wedge pressure 
suggests pulmonary 
venoocclusive disease or 
coexisting left ventricular 
dysfunction 
Cardiac output Increase Increase should be from increased 
stroke volume rather than 
increased heart rate 
Heart rate No significant 
change 
Chronic increased heart rate will 
result in RV failure; watch for 
bradycardia if using high doses of 
diltiazem 
Systemic arterial 
oxygen saturation 
Increase if reduced 
on room air, little 
change if normal 
Decrease in systemic arterial 
oxygen saturation suggests lung 
disease or right-to-left shunt; 
prohibits chronic use 
Pulmonary artery 
(mixed venous) 
oxygen saturation 
Increase Should parallel increase in cardiac 
output and improved tissue 
oxygenation 
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HISTOPATHOLOGICAL CLASSIFICATION OF HYPERTENSIVE 
PULMONARY VASCULAR DISEASE 
 
Classification Arteriopathy Characteristic Histopathological Features
Isolated medial 
hypertrophy[*] 
Medial hypertrophy: increase of medial 
muscle in muscular arteries, muscularization 
of nonmuscularized arterioles; no 
appreciable intimal or luminal obstructive 
lesions; no plexiform lesions 
Plexogenic pulmonary Plexiform and dilation lesions; medial 
hypertrophy; eccentric or concentric laminar 
and nonlaminar arteriopathy, intimal 
thickening; fibrinoid necrosis, arteritis, and 
thrombotic lesions 
Thrombotic pulmonary Thrombi (fresh, organizing, or organized and 
colander lesions); eccentric and concentric 
nonlaminar arteriopathy, intimal thickening, 
varying degrees of medial hypertrophy; no 
plexiform lesions 
Isolated pulmonary arteritis Active or healed arteritis, limited to 
pulmonary arteries; varying degrees of 
medial hypertrophy, intimal fibrosis, and 
thrombotic lesions; no plexiform lesions; no 
systemic arteritis 
Venopathy 
Pulmonary venoocclusive 
disease 
Eccentric intimal fibrosis and recanalized 
thrombi within diseased pulmonary veins 
and venules; arterialized veins, capillary 
congestion, alveolar edema and 
siderophages, dilated lymphatics, pleural and 
septal edema, and arterial medial 
hypertrophy; intimal thickening and 
thrombotic lesions 
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THROMBOTIC PULMONARY ARTERIOPATHY.  
The other major pattern of vascular changes in PAH is that of a 
thrombotic pulmonary arteriopathy. Typical features include medial 
hypertrophy of the arteries and arterioles, with both eccentric and concentric 
nonlaminar intimal fibrosis. The presence of colander lesions, which 
represent recanalized thrombi, is also typical. These lesions are believed to 
arise as a result of primary in situ thrombosis of the small vascular arteries 
and not from recurrent pulmonary embolism. 
Many patients will have characteristics of both patterns of 
arteriopathy of varying degrees. This would suggest that the vascular 
changes from PAH occur across a spectrum, and are likely influenced by 
genetic and environmental factors. 
 
DYSFUNCTIONAL ENDOTHELIUM.  
The dysfunctional pulmonary hypertensive endothelial cell phenotype 
is characterized by uncontrolled proliferation, increased production of 
vasoconstrictor mediators such as endothelin, expression of 5-
lipooxygenase, and decreased synthesis of prostacyclin.. 
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Reduced expression of the endothelial isoform of NO synthase has 
been demonstrated in the pulmonary vasculature and correlates inversely 
with the extent and severity of morphological lesions.  
A striking feature of the pulmonary vasculature in patients with IPAH 
is intimal proliferation and, in some vessels, it causes virtually complete 
vascular occlusion. Several growth factors have been implicated in the 
development of this type of vascular pathology, including basic fibroblast 
growth factor from the endothelium.. 
ION CHANNELS.  
Potassium channels are found throughout the pulmonary vascular bed. 
They consist of voltage-dependent and calcium-dependent potassium 
channels . The role of these channels has been studied primarily in the 
presence of acute hypoxia in animals. It is believed that potassium channels 
modulate adult pulmonary vascular tone. It is probable that calcium channels 
also serve a regulatory role in modulating vascular tone, particularly the L-
type calcium channel. Inhibition of the voltage-regulated potassium channel 
by hypoxia or drugs can produce vasoconstriction and has been described in 
pulmonary artery smooth muscle cells harvested from patients with IPAH... 
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SEROTONIN.  
Elevated plasma levels of serotonin and reduced platelet serotonin 
concentration have been described in IPAH patients. Mutations in the 
serotonin transporter and 5-hydroxytryptamine 2B (5-HT2B) receptor have 
now been reported in patients with IPAH. 
ELASTOLYTIC ENZYMES.  
High elastin turnover and neosynthesis of elastin have been attributed 
to degradation of elastin from the increased activity of serine elastase.. 
Enzymes released from precursor or mature smooth muscle cells activate 
growth factors normally stored in the extracellular matrix, such as basic 
fibroblast growth factor and TGF-b, which are known to induce smooth 
muscle cell hypertrophy and proliferation and increase connective tissue 
protein synthesis. In muscular arteries, release of growth factors would result 
in hypertrophy of the vessel wall. 
OTHER VASCULAR PROTEINS.  
Increased plasma levels of adrenomedullin occur in PAH and hypoxic 
pulmonary hypertension.. Vasoactive intestinal peptide decreases pulmonary 
artery pressure and pulmonary vascular resistance and inhibits platelet 
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activation and smooth muscle cell proliferation. Increased levels have been 
reported in PAH 
 
FAMILIAL PULMONARY ARTERIAL HYPERTENSION.  
Idiopathic PAH has been diagnosed in families worldwide. The 
prevalence of familial PAH (FPAH) is uncertain, but it occurs in at least 6 
percent of cases, and the incidence is likely higher. The age of onset is 
variable and the low penetrance of the gene confers only about a 20 percent 
likelihood of development of the disease. Many individuals in families with 
PAH inherit the gene and have progeny in whom PAH never develops. 
Bone Morphogenetic Protein Receptor Type 2 Gene.  
Using linkage analysis, the locus designated PPH-1 on chromosome 
2q33 led to the discovery of the PPH-1 gene. PPH-1 is the Human Genome 
Organization–approved designation DGB:1381541. The bone 
morphogenetic protein receptor type 2 gene (BMPR-2) codes for a receptor 
member of the TGF-b family . BMPR-2 modulates vascular cell growth by 
activating the intracellular pathways of Smad and LIM kinase. . Recent data 
have supported the hypothesis that the predominant molecular mechanism 
underlying PAH is haploinsufficiency for BMPR-2.  
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Other Genetic Factors.  
There is overexpression of serotonin transporter (5-hydroxytryptamine 
transporter, 5-HTT) in pulmonary arteries and platelets from all the patients 
with PAH. 
Defects in a common vascular signaling pathway involving 
angiopoetin-1 have also been described. Increased signaling has been noted 
which causes phosphorylation of the endothelial-specific TIE-2 receptor. 
This reduces the level of the BMPR-1A receptor which is necessary for 
normal BMPR-2 signaling. 
RIGHT VENTRICULAR FUNCTION 
Right ventricular failure from pulmonary hypertension is a result of 
chronic pressure overload and associated volume overload, with the 
development of tricuspid regurgitation.. The mechanism of right ventricular 
failure in patients with pulmonary hypertension is complex. The chronic 
pressure overload that induces right ventricular hypertrophy and reduced 
contractility has been shown to cause a reduction in coronary blood flow to 
the right ventricular myocardium, which can produce right ventricular 
ischemia, both acutely and chronically. Such right ventricular dysfunction 
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appears to be a result of a reduction in right ventricular coronary artery 
driving pressure. 
LEFT VENTRICULAR FUNCTION.  
On occasion, patients with pulmonary hypertension have a reduced 
left ventricular ejection fraction and even regional wall motion abnormalities 
of the left ventricle. In the past, these findings had been attributed to 
mechanisms related to interventricular dependence, which suggests that in 
some way a dysfunctional right ventricle can lead to a dysfunctional left 
ventricle. Clearly, the shared interventricular septum can affect the function 
of both ventricles. . 
MANAGEMENT  
 
LIFESTYLE CHANGES  
Graded exercise activities, such as bike riding or swimming, in which 
patients can gradually increase their workload and easily limit the extent of 
their work, are thought to be safer than isometric activities. Isometric 
activities such as lifting weights or stair climbing can be associated with 
syncopal events and should be limited or avoided. 
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PREGNANCY ISSUES  
Surgical sterilization should be given strong consideration by women 
with IPAH or their husbands, and pregnancy should be strongly discouraged. 
 
MEDICAL THERAPIES  
Medical therapies have been developed that are targeted at reversing 
the severity of pulmonary hypertension via many different pathways. 
 
DIGOXIN.  
 Digoxin helps prevent the reduction in contractility of the right 
ventricle. Clinically, it has been shown that digoxin can exert a favorable 
hemodynamic effect when given acutely to patients with right ventricular 
failure from pulmonary hypertension.. 
DIURETICS  
These drugs appear to be of marked benefit in symptom relief of 
patients with IPAH. Their traditional role has been limited to patients 
manifesting right ventricular failure and systemic venous congestion. 
However, patients with advanced IPAH can have increased left ventricular 
filling pressures that contribute to the symptoms of dyspnea and orthopnea, 
which can be relieved with diuretics. Diuretics may also serve to reduce 
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right ventricular wall stress in patients with concomitant tricuspid 
regurgitation and volume overload.  Patients with severe venous congestion 
may require high doses of loop diuretics or the use of combined diuretics. . 
 Spironolactone has been demonstrated to enhance the beneficial 
effect of ACE inhibition on mortality in patients with congestive heart 
failure. Given the similarities between left and right heart failure on 
activation of the renin-angiotensin-aldosterone system, it seems reasonable 
to use aldosterone antagonists in patients with pulmonary hypertension. 
SUPPLEMENTAL OXYGEN.  
Hypoxic pulmonary vasoconstriction can contribute to pulmonary 
vascular disease in patients with alveolar hypoxia from parenchymal lung 
disease. Supplemental low-flow oxygen alleviates arterial hypoxemia and 
attenuates the pulmonary hypertension in patients with these disorders. . 
ANTICOAGULANTS.  
Oral anticoagulant therapy is widely recommended for patients with 
PAH.Patients who received warfarin had improved survival over those who 
did not.. The current recommendation is to use warfarin in relatively low 
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doses, as has been recommended for prophylaxis of venous 
thromboembolism, with the international normalized ratio (INR) maintained 
at 2.0 to 3.0 times that of controls. 
VASODILATOR THERAPY  
CALCIUM CHANNEL BLOCKERS.  
Of the vasodilators prescribed for patients with IPAH, calcium 
channel blockers appear to have the widest use.. It has been reported that 10 
to 20 percent of patients with IPAH who are challenged with very high doses 
of calcium channel blockers may manifest a dramatic reduction in 
pulmonary artery pressure and pulmonary vascular resistance, It appears 
essential that high doses (e.g., amlodipine, 20 to 30 mg/day; nifedipine, 180 
to 240 mg/day; diltiazem, 720 to 960 mg/day) be used to realize full benefit.  
PROSTACYCLINS.  
Prostacyclins have been found to be effective in the therapy of 
pulmonary arterial hypertension. Continuous intravenous infusion of 
epoprostenol has been shown in randomized clinical trials to improve 
quality of life and symptoms related to IPAH.. Patients may have a reduction 
in pulmonary vascular resistance of more than 50 percent, even if no acute 
hemodynamic effects are noted.  
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Side effects related to epoprostenol include flushing, headache, 
nausea, diarrhea, and a unique type of jaw discomfort that occurs with 
eating. In most patients, these symptoms are minimal and well tolerated. 
Chronic foot pain and a poorly defined gastropathy with prolonged use 
develop in some patients. .Treprostinil is a stable prostacyclin analogue that 
has pharmacological actions similar to those of epoprostenol, .Iloprost, an 
analogue of prostacyclin, has been approved for use via inhalation. eraprost 
improved exercise capacity and symptoms over a 12-week period but had no 
significant effect on cardiopulmonary hemodynamics or functional class. . 
 
 
ENDOTHELIN RECEPTOR BLOCKERS.  
Bosentan is a nonselective endothelin receptor blocker that is 
approved as a treatment of pulmonary arterial hypertension.  Bosentan 
showed a significant improvement in 6-minute walk distance after 16 weeks 
as compared with placebo. The approved dosage of bosentan is 125 mg 
twice daily. 
PHOSPHODIESTERASE TYPE 5 INHIBITORS.  
Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor  produces 
pulmonary vasodilation by promoting an enhanced and sustained level of 
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cGMP, an identical effect to that of inhaled NO. The recommended dosage 
is 20 mg three times daily, but dosages as high as 80 mg three times daily 
have been used safely. 
Invasive Techniques  
ATRIAL SEPTOSTOMY.  
The rationale for the creation of an atrial septostomy in patients with 
PAH is based on experimental and clinical observations suggesting that an 
intraatrial defect allowing right-to-left shunting in the setting of severe 
pulmonary hypertension might be of benefit. 
The mechanisms responsible for the beneficial effects of atrial 
septostomy remain unclear. Possibilities include increased oxygen delivery 
at rest and/or with exercise, reduced right ventricular end-diastolic pressure 
or wall stress, improvement in right ventricular function as by the Frank-
Starling curve, or relief of ischemia. 
HEART-LUNG AND LUNG TRANSPLANTATION.  
 Transplantation should be reserved for patients with pulmonary 
hypertension who have progressed in spite of optimal medical management. 
It is generally accepted that patients should be considered for transplantation 
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when they have WHO functional class III or IV disease in spite of therapy 
with a parenteral prostacyclin. 
Pulmonary Arterial Hypertension Associated with Congenital Heart 
Disease  
Pulmonary hypertension can develop in adults with an atrial septal 
defect,increased pulmonary blood flow from hyperthyroidism and beriberi, 
patients with pretricuspid shunts, such as atrial septal defect or anomalous 
pulmonary venous drainage. 
 EISENMENGER SYNDROME.  
This refers to any anomalous circulatory communication that leads to 
obliterative pulmonary vascular disease, including pretricuspid and 
posttricuspid shunts The long-term prognosis of patients with Eisenmenger 
syndrome appears to be better than that of patients with other conditions 
associated with pulmonary hypertension.. 
Pulmonary Arterial Hypertension Associated with Connective Tissue 
Diseases  
Scleroderma, including the CREST syndrome, is the most common 
cause of pulmonary hypertension in connective tissue disease states. 
Scleroderma is associated with pulmonary hypertension in as many as one 
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third of patients and with CREST syndrome in as many as 50 percent.. 
Patients with systemic lupus erythematosus also have pulmonary 
hypertension, although less commonly than patients with scleroderma. 
Mixed connective tissue disease is a less common form of connective tissue 
disease, but pulmonary hypertension may occur in as many as two thirds of 
these patients. Pulmonary hypertension has also been described in patients 
with polymyositis, dermatomyositis, and rheumatoid arthritis. 
Pulmonary Arterial Hypertension Associated with Portal Hypertension  
Pulmonary abnormalities have been commonly associated with the 
development of hepatic cirrhosis and portal hypertension and include 
hypoxemia and intrapulmonary shunting, portal-pulmonary shunting, 
impaired hypoxic pulmonary vasoconstriction, and pulmonary hypertension. 
Pulmonary Arterial Hypertension Associated with Human 
Immunodeficiency Virus Infection  
Although well documented, it remains unclear how HIV infection 
results in an increased incidence of PAH in HIV-infected patients. A direct 
pathogenic role of HIV seems unlikely, inasmuch as no viral constituents 
have been detected in the vascular endothelium of these patients. On the 
other hand, reports of pulmonary arteriopathy with intimal proliferation in 
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monkeys experimentally infected with the simian immunodeficiency virus 
and in a murine model of acquired immunodeficiency syndrome have 
suggested a pathogenetic link between infection with an immunodeficiency 
virus and the development of PAH.. 
Pulmonary Arterial Hypertension Related to Anorexigens  
Aminorex, fenfluramine have been demonstrated in the development of 
PAH  
Pulmonary Hypertension Related to Sickle Cell Disease  
Cardiopulmonary complications are common in sickle cell disease. 
The cause of pulmonary hypertension, which has been reported in 20 to 32 
percent of sickle cell disease patients, is multifactorial, with contributing 
factors including hemolysis, impaired nitric oxide bioavailability, chronic 
hypoxemia, high cardiac output, thromboembolism, and parenchymal and 
vascular injury caused by sequestration of sickle erythrocytes, chronic liver 
disease, and asplenia. 
Persistent Pulmonary Hypertension of the Newborn  
Three forms of persistent pulmonary hypertension of the newborn 
have been described. In the hypertrophic type, the muscular tissue of the 
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pulmonary arteries is hypertrophied and extends peripherally to the acini.  In 
the hypoplastic type, the lungs, including the pulmonary arteries, are 
underdeveloped, usually as the result of a congenital diaphragmatic hernia or 
prolonged leakage of amniotic fluid. The cross-sectional area of the 
pulmonary vascular bed is inadequate for normal neonatal pulmonary blood 
flow. In the reactive type, lung histology is presumably normal but 
vasoconstriction causes pulmonary hypertension. High levels of 
vasoconstrictive mediators such as thromboxane, norepinephrine, and 
leukotrienes may be responsible and may result from streptococcal infection 
or acute asphyxia at birth. 
Pulmonary Venoocclusive Disease  
Pulmonary venoocclusive disease is a rare form of PAH.[60] The 
histopathological diagnosis is based on the presence of obstructive eccentric 
fibrous intimal pads in the pulmonary veins and venules.  
Pulmonary Capillary Hemangiomatosis  
Pulmonary capillary hemangiomatosis was first described in 1978 as a 
very rare cause of pulmonary hypertension. 
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Pulmonary Venous Hypertension  
Pathophysiology  
Increased resistance to pulmonary venous drainage is a mechanism 
common to several conditions of diverse causes in which pulmonary 
hypertension occurs. Altered resistance to pulmonary venous drainage may 
be the result of diseases affecting the left ventricle or pericardium or mitral 
or aortic valves, or of rare entities such as cor triatriatum and left atrial 
myxoma. 
PULMONARY ARTERIAL VASOCONSTRICTION.  
Considerable variability in pulmonary arterial vasoconstriction occurs 
in response to pulmonary venous hypertension. Marked reactive pulmonary 
hypertension with pulmonary artery systolic pressures in excess of 80 mm 
Hg occurs in somewhat less than one third of patients whose pulmonary 
venous pressures are elevated more than 25 mm Hg. The fact that severe 
reactive pulmonary hypertension develops in fewer than one third of patients 
with severe mitral stenosis suggests a broad spectrum of pulmonary vascular 
reactiv-ity to chronic increases in pulmonary venous pressure. . 
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Sarcoidosis  
Pulmonary hypertension is most commonly the result of chronic 
severe fibrocystic sarcoidosis. Patients have chronic progressive dyspnea 
with effort, a chest radiograph demonstrating severe diffuse interstitial 
fibrotic lung disease, and pulmonary function test results that reflect severe 
restrictive physiology and hypoxemia. In these cases, the resulting 
pulmonary hypertension is usually mild to moderate and typical of patients 
presenting with restrictive lung disease of any cause. 
Pulmonary Arterial Hypertension Associated with Disorders of the 
Respiratory System  
Diseases of the lung parenchyma are a common cause of pulmonary 
hypertension. The pathogenic mechanisms that can lead to pulmonary 
hypertension in this setting are shown in Table .  
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Potential Pathogenic Mechanisms Leading to Pulmonary Arterial 
Hypertension and Cor Pulmonale 
 
Mechanisms Example(s) 
Primary 
Anatomical decrease in cross-sectional area 
(vessel destruction; encroachment on lumen by 
hypertrophy) of the pulmonary resistance vessels
Interstitial fibrosis and 
granuloma 
Vasoconstriction of pulmonary resistance vessels Hypoxia and acidosis 
Contributory 
Large increments in pulmonary blood flow Exercise 
Increased pressures on the left side of the heart 
and pulmonary veins 
Left ventricular failure or 
pulmonary venoocclusive 
disease 
Increased viscosity of the blood Secondary polycythemia 
or chronic hypoxia 
Unproved 
Compression of pulmonary resistance vessels by 
raised alveolar pressures in their vicinity 
Asthmatic bronchitis 
Bronchial arterial-pulmonary arterial 
anastomoses 
Expanded bronchial 
circulation 
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PULMONARY HYPERTENSION IN COPD.  
Most commonly, pulmonary hypertension in COPD patients has 
multiple causative factors, including pulmonary vasoconstriction caused by 
alveolar hypoxia, acidemia, and hypercarbia, the compression of pulmonary 
vessels by the high lung volume, the loss of small vessels in the vascular bed 
in regions of the emphysema and lung destruction, and increased cardiac 
output and blood viscosity from polycythemia secondary to hypoxia.. Of 
these, hypoxia is the most important factor and is associated with 
pathological changes that occur characteristically in the peripheral 
pulmonary arterial bed. 
Key Indicators for Considering a Diagnosis of Chronic Obstructive 
Pulmonary Disease (COPD)[*] 
 
Stage Characteristics 
Chronic cough Present intermittently or every day 
  Often present throughout the day; seldom only 
nocturnal 
Chronic sputum 
production 
Any pattern of chronic sputum production may indicate 
COPD 
Dyspnea that is Progressive (worsens over time) 
Persistent (present every day) 
Described by the patients as “increased effort to 
breathe,” “heaviness,” “air hunger,” or “gasping” 
Worse on exercise 
Worse during respiratory infections 
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Interstitial Lung Diseases  
Interstitial lung diseases represent various conditions that involve the 
alveolar walls, perialveolar tissue, and other contiguous supporting 
structures. Pulmonary hypertension occurs in patients with interstitial lung 
diseases and is often associated with obliteration of the pulmonary vascular 
bed by lung destruction and fibrosis. . 
ADULT CYSTIC FIBROSIS.  
Cystic fibrosis is the most common lethal genetic disease in whites 
and occurs in approximately 1 of every 2000 live births. As the disease 
progresses, patients develop disabling lung disease and eventually 
respiratory failure, pulmonary hypertension, and cor pulmonale.. 
Sleep-Disordered Breathing and Pulmonary Hypertension  
Observational studies have demonstrated a wide variation in the 
incidence of pulmonary hypertension as a complication of sleep apnea, with 
a wide range of severity. The diagnosis of pulmonary hypertension in 
obstructive sleep apnea patients is also clouded by the coexistence of 
systemic hypertension, obesity, and diastolic dysfunction.. 
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Alveolar Hypoventilation Disorders  
Alveolar hypoventilation disorders are characterized by hypoxemia 
and mechanical disorders of the ventila-tory system which, in concert, may 
cause pulmonary hypertension. 
CHEST WALL DISORDERS.  
Thoracovertebral deformities like idiopathic kyphoscoliosis, spinal 
tuberculosis, congenital spinal developmental abnormalities, spinal cord 
injury and other childhood myelopathies, ankylosing spondylitis, or other 
congenital and acquired muscular skeletal conditions, such as pectus 
excavatum. 
NEUROMUSCULAR DISEASE.  
Disorders like  myopathic infiltrating diseases or muscular dystrophy , 
amyotrophic lateral sclerosis, myasthenia gravis, poliomyelitis, and Guillain-
Barré syndromecause pulmonary hyprertension..  
DIAPHRAGMATIC PARALYSIS.  
Bilateral diaphragmatic paralysis is an uncommon and rarely 
recognized cause of pulmonary hypertension. Diaphragmatic paralysis is a 
result of phrenic nerve injury, which can be traumatic or secondary to an 
underlying motor neuron disease. It may occur after cardiac surgery, as a 
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manifestation of Lyme disease, after radiation therapy, or as a manifestation 
of other neurological disorders.. 
Pulmonary Hypertension Caused by Chronic Thrombotic or Embolic 
Obstruction of the Pulmonary Arteriees  
Chronic thromboembolic pulmonary hypertension is an 
underdiagnosed disorder, and the true prevalence is still unclear. Pulmonary 
embolism, either as a single episode or as recurrent events, is thought to be 
the initiating process, followed by progressive vascular remodeling.  
Pulmonary Hypertension Caused by Disorders Directly Affecting the 
Pulmonary Vasculature  
 
Schistosomiasis  
Although schistosomiasis is extremely rare in North America, 
hundreds of millions of people are affected worldwide, particularly in 
developing countries. The development of pulmonary hypertension almost 
always occurs in the setting of hepatosplenic disease and portal 
hypertension. 
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MATERIALS  AND  METHODS 
 
This study was performed in the Department of Cardiology, Government 
General Hospital, Chennai, during the year 2006 – 2009,after approval from 
the Institutional Ethical Committee, Madras Medical College, Chennai – 3.                        
(Ref – K . Dis.No.002909 / P & D3 /Ethics /Dean /GGH /09) 
 
STUDY  INDICATION :                         
 To differentiate primary PHT from secondary PHT with the use of           
MPI [Myocardial Performance Index]  [TEI INDEX ] 
 To study the effects of primary PHT and secondary PHT on right            
ventricular function. 
 To study the effects of primary PHT and secondary PHT on left           
ventricular function. 
 To estimate the mean pulmonary artery pressure (mPAP) in primary 
PHT and secondary PHT. 
 To estimate the pulmonary capillary wedge pressure (PCWP) in 
primary PHT and secondary PHT.  
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STUDY  GROUP  SELECTION 
 
                               STUDY GROUP :    CONSISTED 60 PERSONS. 
 
       GROUP A :  10 CASES OF PRIMARY PULMONARY HYPERTENSION 
       GROUP B :  40 CASES OF SECONDARY PULMONARY HYPERTENSION 
       GROUP C :  10 NORMAL PERSONS [CONTROL GROUP] 
 
 
        GROUP  B 
 
 10 Cases ASD with Reversal 
 10 Cases VSD with Reversal 
 10 Cases PDA with Reversal 
5 Cases Pulmonary Embolism  
 5 Cases COPD 
 
 
 
 
 
 
STUDY DESIGN :  
CASE CONTROL STUDY [OBSERVATIONAL STUDY ] 
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AGE  DISTRIBUTION  
 
             AGE IN YEARS 
              GROUP A                   10 – 25 
              GROUP B                   18 – 54 
              GROUP C                   20 – 50 
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SEX DISTRIBUTION  
 
 
 
 
                     MALES        FEMALES             
         GROUP A              2              8 
         GROUP B              22              18 
         GROUP C              5              5 
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SMOKING HABITUS 
 
 
 
          SMOKER NONSMOKER 
         GROUP A 2 8 
         GROUP B 18 22 
         GROUP C 2 8 
 
 
 
 
 
 
 
ALCOHOL  ABUSE  HABITUS 
 
 
 
 
                     ALCOHOLIC  NONALCOHOLIC       
         GROUP A 1 9 
         GROUP B 10 30 
         GROUP C 1 9 
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BLOOD GLUCOSE DISTRIBUTION IN THE THREE 
GROUPS  
 
 
                     DIABETIC  NONDIABETIC          
         GROUP A              1              9 
         GROUP B              10              30 
         GROUP C              2              8 
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BLOOD  PRESSURE  DISTRIBUTION 
IN  THE  THREE GROUPS  
 
 
 
 
                     
HYPERTENSIVE 
       
NONHYPERTENSIVE  
         GROUP A              1              9 
         GROUP B              12              28 
         GROUP C              3              7 
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The following parameters were done to differentiate primary pulmonary 
hypertension from secondary pulmonary hypertension. 
 
1) RV MPI 
2) LV MPI 
3) MITAL E VELOCITY [m/sec] 
4) MITRAL INFLOW PROPAGATION  VELOCITY[cm/sec] Vp 
5) PCWP [mmHg] 
6) RV dP/dT   [mmHg/sec] 
7) MPAP  [mmHg/sec] 
8) LV dP/dt   [mmHg/sec] 
9) LVOT Acceleration (m/sec2) 
 
 Echo Machine  Philips IE33 was used for Echocardiographic 
Parameters.  
 Philips Integris angiographic machine was used for 
Angiographic Parameters. 
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RESULTS AND DATA ANALYSIS 
 
RV  MPI   
 
                 Normally RV MPI  does  not  exceed  0.2.                      
In  GROUP A, RV MPI  always exceeds  0.7.                                 
In  GROUP B,  RV MPI  is  in  the  range  of  0.3  to  0.4.              
In  GROUP C, RV MPI  is  kept  in  the  normal  range. 
 
 RV MPI MEAN P Value 
 GROUP A 0.7 – 0.96 0.8 < 0.01 
 GROUP B 0.3 – 0.4 0.36 < 0.02 
 GROUP C 0.12 – 0.18 0.15 <0.01 
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LV  MPI  
                       Normally LV MPI  does  not  exceed  0.4.         
In  GROUP A, LV MPI  is  in  the  range  of  0.42 – 0.48.           
In  GROUP B, LV MPI  is  in  the  range  of  0.4 – 0.46.             
In  GROUP C, LV MPI  is  kept  in  the  normal  range 
 
 RV MPI MEAN P Value 
 GROUP A 0.42 – 0.48 0.45 < 0.01 
 GROUP B 0.4 – 0.46 0.43 < 0.02 
 GROUP C 0.26 – 0.36 0.32 < 0.01 
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MITRAL  E  VELOCITY  
 
Normally, E VELOCITY is in the range of 0.6 – 0.9 m / sec.  
In Group A, E VELOCITY is in the range of 0.52 – 0.72 m /sec. 
In Group B, E VELOCITY is  in  the  range  of  0.7 – 1.6 m /sec. 
In  Group C, E VELOCITY is  kept  in  the  normal  range 
 
 
 MITRAL E 
VELOCITY (m /sec) 
MEAN P Value 
 GROUP A 0.52 – 0.72 0.62 < 0.01 
 GROUP B 0.7 – 1.6 1.2 < 0.02 
 GROUP C 0.6 – 0.7 0.65 < 0.01 
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MITRAL INFLOW PROPAGATION VELOCITY (cm / sec): 
Vp   
 
Normally, Vp is more than 50 cm / sec.                                        
In GROUP A, Vp is in the range of  48 – 50  cm / sec.                  
In GROUP B, Vp is in the range of  20 – 40  cm / sec.                 
In GROUP C, Vp is  kept  in  the  normal  range 
 
 Vp ( cm / sec ) MEAN P Value 
 GROUP A 48 – 50 54 < 0.01 
 GROUP B 20 – 42 34 < 0.02 
 GROUP C 48 – 90 70 < 0.01 
 
 
MITRAL INFLOW PROPAGATION 
VELOCITY [CM / SEC ] IN THE 
THREE GROUPS
0
10
20
30
40
50
60
70
80
90
PRIMARY
PHT
SECONDARY
PHT
CONTROL
MINIMUM
3-D Column 2
MAXIMUM
Vp
m / sec
 
 
 
 73
 
 
PULMONARY CAPILLARY WEDGE PRESSURE (mmHg ): 
 
      Normal  PCWP  is  in  the  range  of  8 – 12  mmHg.                                    
In GROUP A, PCWP is in the range of  10 – 12 mmHg.                 
In GROUP B, PCWP is in the range of  22 – 26 mmHg.                
In GROUP C, PCWP is  kept  in  the  normal  range. 
 
 PCWP ( mmHg ) MEAN P Value 
 GROUP A 10 – 12 11 < 0.01 
 GROUP B 22 – 26 24 < 0.02 
 GROUP C 7 – 12 9 < 0.01 
 
PULMONARY CAPILLARY WEDGE 
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MEAN PULMONARY ARTERY PRESSURE ( MPAP ) : 
 
Normal  MPAP  is  in  the  range  of  10 – 15  mmHg.                                     
In GROUP A, MPAP is in the range of  50 – 80 mmHg.                 
In GROUP B, MPAP is in the range of  30 – 50 mmHg.                
In GROUP C, PCWP is  kept  in  the  normal  range. 
 
 MPAP ( mmHg ) MEAN P Value 
 GROUP A 50 -- 80 70 < 0.01 
 GROUP B 30 -- 50 42 < 0.02 
 GROUP C 10 -- 15 12 < 0.01 
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                              RV dP / dT : ( mmHg / sec )   : 
 
Normal  RV dP / dT  is  in  the  range  of  620 --740  .                                     
In GROUP A,  RV dP / dT  is  in  the  range  of  200 – 500.                 
In GROUP B,  RV dP / dT  is  in  the  range  of  350 – 550.                
In GROUP C,  RV dP / dT  is  kept  in  the  normal  range. 
 
      
RV dP / dT :  
( mmHg / sec ) 
         
MEAN P Value 
 GROUP A 200 -- 500 300 < 0.01 
 GROUP B 350 -- 550 450 < 0.02 
 GROUP C 660 -- 700 680 < 0.01 
 
RV dp /dt [mmHg / sec ] IN THE 
THREE GROUPS
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                            LV dP / dT : (mmHg / sec ) : 
 
Normal  LV dP / dT  is  in  the  range  of  1000 -- 1600 .                                     
In GROUP A,  LV dP / dT  is  in  the  range  of  800 – 900.                 
In GROUP B,  LV dP / dT  is  in  the  range  of  850 – 950.                
In GROUP C,  LV dP / dT  is  kept  in  the  normal  range. 
 
 
 LV dP / dT : 
(mmHg / sec ) : 
MEAN P Value 
 GROUP A 800 -- 900 850 < 0.01 
 GROUP B 850 -- 950 900 < 0.02 
 GROUP C 1200 -- 1600 1300 < 0.01 
 
   
LV dp /dt [mmHg / sec ] IN THE 
THREE GROUPS
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                            LVOT  ACCELERATION 
 
LVOT Acceleration was calculated in those cases without Mitral 
Regurgitation 
 
NORMAL VALUE : MORE THAN 11 m/sec2  
 
 
 LVOT 
ACCELERATION 
MEAN P Value 
 GROUP A 10-12 11 < 0.01 
 GROUP B 10-14 12 < 0.02 
 GROUP C 12-14 13 < 0.01 
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DISCUSSION 
       
MYOCARDIAL PERFORMANCE INDEX  [ MPI ] 
[ TEI INDEX ] 
           
 
DEFINITION 
 
z MPI (or Tei index) is defined as ratio of the sum of the isovolumic 
contraction time (IVCT) and isovolumic relaxation time (IVRT) 
divided by the systolic ejection time (ET)                                            
                                                                                          
                                         IVCT  +  IVRT  
                 MPI =     ------------------------------ 
                                                  ET 
                   MPI   = Myocardial Performance Index 
                   IVCT = Isovolumic Contraction Time 
                   IVRT = Isovolumic Relaxation Time 
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                                             NORMAL VALUES 
 
z                    LV MPI  =  LESS THAN 0.4 
 
z                    RV MPI =  LESS THAN 0.2 
 
                                MPI WITH TIME INTERVALS 
 
z MPI is not limited by the geometric shape of the ventricle, a fact that 
is important in these patients who usually have distorted ventricular 
geometry.   
z The MPI also includes changes of the IVRT, a diastolic time interval. 
The systolic and diastolic time intervals are easily obtained by routine 
Doppler techniques during standard echocardiographic examination 
and are simple to measure, with excellent reproducibility. In addition, 
MPI is independent of heart rate. 
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          WHY  RV MPI  IS  LESS  THAN  LV MPI 
 
                       2 REASONS  ARE  SUGGESTED.: 
 
z 1. RV IVRT is almost nonexistent. Since IVRT is present in the 
numerator aspect of TEI index the value of the fraction decreases. 
 
z 2. As far as the inertia is concerned, RV has to pump blood against 
low impedence pulmonary vascular system.Hence,ejection time 
increases. Since ET is present in the denominator aspect of the TEI 
index,the value of the fraction decreases.[ACCORDING TO 
NEWTON”S FIRST LAW OF MOTION] 
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          NEWTON”S FIRST LAW OF MOTION 
 
z Every body continues in its state of rest or of motion until it is 
compelled by an external force acting on it. 
    This is called inertia as the corollary. 
 
 
              NEWTON”S SECOND LAW OF MOTION. 
 
z The rate of change of momentum is directly proportional to the 
impressed force acting on it and takes part in the direction of the force 
 
z Because of low impressed force,momentum decreases. 
So, velocity of blood decreases. Hence RV takes sufficient time to 
eject its blood. So, ejection time increases. Thereby,RV  MPI 
decreases. 
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                                          RV MPI 
 
 
This is defined as ratio of the sum of the RV isovolumic 
contraction time (IVCT) and RV isovolumic relaxation time 
(IVRT) divided by the RV systolic ejection time (ET)                                            
 
 
 
 
 
 
                                          IVCT + IVRT  =  190 msec 
                                                       
                                                   ET           =  229 msec 
 
                                          RV MPI           =  190 / 229  =  0.86 
                                         
     
In primary PHT RV MPI was more than 0.7. The mean value 0.8 with 
a  P Value of 0.01 which is statistically significant. In secondary PHT RV 
MPI was in the range of 0.3 to 0.4 with a mean value of 0.36 (P Value 0.02) 
which is also statically significant.  
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LV MPI 
 
This is defined  as ratio of the sum of the LV isovolumic contraction time 
(IVCT) and LV isovolumic relaxation time (IVRT) divided by the LV 
systolic ejection time (ET)                                                                          
 
                                          IVCT + IVRT  =  113 msec 
                                                    ET           =  204 msec 
                                          LV MPI            =  113 / 204  =  0.55   
 
                                                              
                                                                                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  MITRAL E VELOCITY 
 
 
In both forms of PHT, LV MPI was within the normal range.  
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MITRAL  E  VELOCITY 
 
This is calculated as follows. 
            
                   The sample volume is kept in between the tips of the anterior 
and posterior mitral leaflets.Now,pulse Doppler of the mitral valve is 
displayed.The peak early diastolic filling velocity is calculated.This is called 
MITRAL E VELOCITY. 
 
 
Here MITRAL E VELOCITY is 0.48 m / sec 
 
In Primary PHT it was 0.52 – 0.72m/sec. But in secondary PHT it was 
in the range of 0.7-1.6 m/sec. So in primary PHT, the diastolic function is 
affected more. 
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MITRAL INFLOW PROPAGATION VELOCITY [VP ] 
 
This is defined as the the tangent [slope ]  of the innermost colour 
spectrum of the mitral inflow jet when the sample volume is kept at 4 cm 
away from the mitral  leaflets inside the LV cavity. 
 
NORMAL VALUE : 
 
             MORE THAN 50 CM/SEC 
 
 
 
     Here  Vp is  68.5 cm / sec.                                      
 
In primary PHT it was in the normal range. In secondary PHT it was 
grossly reduced. 
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                                    RV dP / dT 
 
z RV dP/dT was calculated from the TR jet.  
z The change in pressure between 1m/sec and 2 m/sec was  
    divided by the time interval between these two velocities. 
z NORMAL VALUE : 
         680 +/- 60 mmHg/sec 
 
 
         dP  =  12 mmHg 
         dT  =  21 msec 
RV  dP / dT =  12000 / 21 =  570 mmHg / sec 
 
In primary PHT RV dP /dT was grossly  affected. In Secondary PHT 
RV dP/dT was mildly affected. So RV dysfunction is more in primry 
PHT.                                       
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LV dP / dT 
 
z This was calculated from the MR jet. 
 
z The change in pressure between 1m/sec and   3m/sec was divided by 
the time interval between these two velocities 
 
z Normal value : 
 
z        More than 1000 mmHg/sec 
z        750 – 1000 mmHg/sec =mild LVD 
z        500 – 750   mmHg/sec =moderate LVD 
z        Less than 500 mmHg/sec = severe 
 
 
 
                                      dP  =  32 mmHg 
                         dT  =  21 msec 
                        LV dP / dT =  32000 / 21 =  1524 mmHg / sec 
 
In both forms of PHT, LV dP/dT was mildly reduced. So LV function 
is mildly reduced in both forms of PHT. 
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PULMONARY CAPILLARY WEDGE PRESSURE 
(PCWP) 
 
     PCWP was calculated by the following formula : 
 
z     PCWP  =   [5.27 X E/Vp ] + 4.6  (Ref. JK. OH-Manual) 
 
z              E  =  mitral E velocity 
 
                  Vp =  mitral inflow propagation  
                            velocity 
 
z    The value is obtained in mmHg 
 
               The PCWP is calculated by right heart heart catheterization. 
               For this, through the right femoral vein approach,the cournard 
catheter is inserted into the right femoral vein by modified Seldinger 
technique and positioned in the pulmonary capillary wedge.The mean value 
is obtained from 3recordings.                                            
 
Pulmonary Capillary Wedge Pressure was within normal range in 
primary PHT. In secondary PHT it was elevated more than 22mmHg 
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MEAN PULMONARY ARTERY PRESSURE( MPAP ) 
 
MPAP was calculated as follows: 
 
              1. ALZEBRAIC  METHOD : 
                  ---------------------------------- 
 
                                             3[PAEDP] + PP 
                          MPAP = ------------------------- 
                                                         3 
 
 
2. IN THE PRESENCE OF PR :   
                  [MASUYAMA] 
                 ------------------------------------------------------------ 
                                                                                           2 
                        MPAP = 4 X [ PEAK PR VELOCITY ] 
 
 
            3.  IN THE ABSENCE OF PR : [MAHAN] 
                   ---------------------------------------------------- 
                        
                       MPAP =   0.79 – 0.45[RVOT Act] 
      
           4.   SIMPLEST  METHOD : 
                   
 
                      MPAP =   0.61 X  SPAP +  2  
 
 
The MPAP was more than 50mmHg in Primary PHT. The MPAP was 
less than 50mmHg in Secondary PHT. 
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LVOT ACCELERATION (m/sec) 
 
 
LVOT Acceleration was calculated in those cases without Mitral 
Regurgitation 
 
NORMAL VALUE : MORE THAN 11 m/sec2  
 
 
 LVOT 
ACCELERATION 
MEAN P Value 
 GROUP A 10-12 11 < 0.01 
 GROUP B 10-14 12 < 0.02 
 GROUP C 12-14 13 < 0.01 
 
 
In both forms of PHT LVOT Acceleration was in the normal range. 
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DIFFERENCE BETWEEN RV MPI 
AND LV MPI IN PRIMARY PAH 
(*P < .05). 
 
 
 
 
 
 
 
 
 
 
 
 
 93
      
RV MPI CORRELATED WITH MPAP     
                             (MPAP)  
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CONCLUSION 
 
 
RESULTS 
 
z In primary  pulmonary hypertension, RV MPI ranged from 0.6 to 1.0. 
But in secondary pulmonary hypertension, RV MPI ranged from 0.3 
to 0.4. 
z In primary pulmonary hypertension, pulmonary capillary wedge 
pressure is in the normal range. But in secondary pulmonary 
hypertension, pulmonary capillary wedge pressure was more than            
22 mmHg. 
z In primary pulmonary hypertension RV dp/dt decreases grossly. But 
in secondary pulmonary hypertension, RV dp/dt mildly decreases.  
z In primary pulmonary hypertension, mean pulmonary artery pressure 
was above 50 mmHg. But in secondary pulmonary hypertension, 
mean pulmonary artery pressure was below 50mmHg. 
z Primary pulmonary hypertension has major impact on diastolic 
dysfunction than secondary pulmonary hypertension. 
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    GLOSSARY AND ACRONYMS  
PHT     --  Pulmonary Hypertension 
 
IPAH   --  Idiopathic Pulmonary Arterial  Hypertension  
 
MPAP  –  Mean Pulmonary Artery Pressure 
 
SPAP   --  Systolic Pulmonary Artery Pressure 
 
PAOP  –  Pulmonary Artery Occlusion Pressure 
 
PCWP –  Pulmonary Capillary Wedge Pressure 
 
MPI    --  Myocardial  Performance  Index 
 
PVR   --   Pulmonary Vascular Resistance 
 
COPD –  Chronic  Obstructive Pulmonary Disease 
 
c GMP –  cyclic  Guanosine Monophosphate 
 
PDE 5  --  Phospho Diesterase inhibitor 5 
 
5HTT   --  5 Hydroxy Tryptamine Transporter 
 
BMPR2 -- Bone Morphogenetic Protein Receptor type 2 gene 
 
BNP       -- Brain Natriuretic Peptide 
 
TGF-b   -- Transforming  Growth  Factor beta 
 
FPAH    –  Familial Pulmonary Arterial  Hypertension 
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GROUP A :PRIMARY 
PULMONARY   HYPERTENSION 
 
 
 
NAME AGE SEX SMO
KER 
ALC
OHO
LIC 
DIAB
ETIC 
HI
GH   
BP 
RV 
MPI 
LV 
MPI 
 E 
VEL
OCI
TY 
 
cm 
Vp 
 
 
cm 
PCWP 
 
 
mm 
Hg 
MP 
AP 
 
mm
Hg 
RV 
DP/DT 
 
mm 
Hg / 
sec 
LV 
DP/DT 
 
Mm 
Hg / 
sec 
DIASTO
LIC 
DYSFUN
CTION 
 
GRADES 
NAGAN 20  M YES YES N N 0.70 0.42 60 60 7 10 260 825     1 
LAKSHMI 22  F NO NO N N 0.82 0.44 66 58 12 10.5 300 850     3 
KALA 24  F NO NO N N 0.92 0.42 65 52 7 10.5 500 800     1 
NEHRU 10  M YES NO Y Y 0.96 0.48 63 72 11 10.5 200 900     2 
BAMA 25  F NO NO N N 0.74 0.46 66 60 8 11 400 810     2 
RUKMANI 16  F NO NO N N 0.72 0.46 66 58 11 11.5 450 870     1 
MAYEE 14  F NO NO N N 0.88 0.44 69 59 8 10.5 350 880     2 
NAGALA 14  F NO NO N N 0.84 0.45 70 60 10 11.5 400 850     1 
SOUNDRA 18  F NO NO N N 0.77 0.47 64 56 9 12 300 840     1 
REKA 20  F NO NO N N 0.76 0.46 62 54 10 12 250 900     1 
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GROUP B : SECONDARY 
PULMONARY HYPERTENSION 
NAME AGE SEX SMO
KER 
ALC
OHO
LIC 
DIAB
ETIC 
HI
GH   
BP 
RV 
MPI 
LV 
MPI 
 E 
VE
LO
CI
TY 
cm 
Vp 
 
 
 
 
cm 
PCWP 
 
 
 
mm 
Hg 
MP 
AP 
 
 
mm
Hg 
RV 
DP/DT 
 
 
mm 
Hg / 
sec 
LV 
DP/DT 
 
 
nm 
Hg / 
sec 
DIASTO
LIC 
DYSFUN
CTION 
 
GRADES 
RAJ 30  M YES NO N N 0.32 0.40 70 42 22 30 350 850     1 
MALA 22  F NO NO N N 0.35 0.46 160 20 26 32 350 860    NO 
ASHOK 44  M YES NO Y Y 0.36 0.41 75 38 23 34 400 870    NO 
MARY 26  F NO NO N N 0.34 0.45 93 25 25 36 400 880    NO 
RAGU 48  M NO NO N N 0.32 0.42 76 30 24 38 450 890    NO 
GEETHA 40  F NO NO N N 0.38 0.44 146 40 22 40 450 900    NO 
SEKAR 46  M YES NO N N 0.38 0.45 98 40 22 42 500 910    NO 
STELLA 44  F NO NO Y Y 0.39 0.46 94 38 22 44 500 920 NO 
AKBAR 48  M YES NO N Y 0.40 0.40 74 20 26 46 550 930 NO 
BEEVI 50  F NO NO Y Y 0.35 0.46 150 20 26 48 550 940 NO 
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NAME AGE SEX SMO
KER 
ALC
OHO
LIC 
DIAB
ETIC 
HI
GH   
BP 
RV 
MPI 
LV 
MPI 
 E 
VE
LO
CI
TY 
 
cm 
Vp 
 
 
 
 
 
cm 
PCWP 
 
 
 
mm 
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DYSFUN
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GRADES 
                
KHAN 40  M YES NO Y Y 0.31 0.41 70 21 26 50 350 950 NO 
BANU 32  F NO NO N N 0.33 0.45 96 28 23 48 400 950 NO 
VICTOR 34  M YES NO N N 0.35 0.42 75 30 23 46 450 940 NO 
RANI 36  F NO NO N N 0.37 0.43 83 27 23 44 500 930 NO 
GOVINDA 48  M YES NO N N 0.39 0.44 96 24 25 42 550 920 NO 
SANTHA 46  F NO NO N N 0.30 0.40 76 24 25 40 500 910 NO 
KUPPU 54  M YES NO N N 0.32 0.40 70 25 25 38 450 900 NO 
VALLI 44  F NO NO Y N 0.34 0.46 156 30 24 36 400 890 NO 
NAGUBAI 48  F NO NO N N 0.36 0.46 160 28 24 34 350 880 NO 
LALU 50  M YES NO Y Y 0.38 0.41 72 32 24 32 550 870 NO 
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GRADES 
RAVI 40  M YES YES N N 0.40 0.41 80 42 22 30 350 860     1 
BALU 32  M YES YES N N 0.38 0.45 96 40 22 31 450 850 NO 
RAMAN 44  M YES YES N N 0.36 0.45 95 42 22 32 550 850 NO 
JAYARAM 36  M YES YES Y Y 0.34 0.42 73 40 22 33 400 860 NO 
KARTHIK 38  M YES YES N N 0.32 0.42 76 20 26 34 500 870 NO 
SRIRAM 36  M YES YES N N 0.30 0.44 86 22 26 35 550 880 NO 
SRINIVAS 40  M YES YES N N 0.31 0.44 109 24 26 36 450 890 NO 
BASKAR 44  M YES YES Y Y 0.33 0.43 80 23 26 37 350 900 NO 
SUBBU 48  M YES YES N Y 0.35 0.43 84 36 23 38 400 910 NO 
JUSTIN 50  M YES YES N Y 0.37 0.40 72 38 23 39 500 920     1 
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GRADES 
JACOB 30  M NO NO N N 0.39 0.40 70 38 23 40 350 930     1 
KUMAR 32  M NO NO N N 0.31 0.41 76 34 23 41 450 940 NO 
SANTHI 34  F NO NO N N 0.30 0.41 75 26 25 42 550 950 NO 
HEMA 26  F NO NO N N 0.39 0.42 73 24 25 43 500 950 NO 
DEVI 28  F NO NO N N 0.32 0.42 76 25 25 44 400 930 NO 
DHANAM 36  F NO NO N N 0.38 0.43 86 26 25 45 550 910 NO 
JANAKI 40  F NO NO N N 0.33 0.43 79 32 24 46 450 890 NO 
MANGAI 44  F NO NO N N 0.37 0.44 90 34 24 47 350 870 NO 
DEVIKA 48  F NO NO Y Y 0.34 0.44 94 33 24 48 400 850 NO 
PADMINI 50  F NO NO Y Y 0.36 0.45 132 34 24 49 500 950     1 
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GROUP C : CONTROL  POPULATION 
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GRADES 
NAGU 20  M YES YES N N 0.12 0.26 60 48 7 10 660 1200 NO 
JEYA 22  F NO NO N N 0.12 0.34 66 54 12 15 665 1600 NO 
SAKILA 24  F NO NO N N 0.12 0.34 65 56 7 14.5 670 1250 NO 
JAWAL 26  M NO NO Y Y 0.18 0.36 63 50 11 10.5 700 1550 NO 
GOVIND 28  M YES NO N N 0.18 0.35 66 90 8 14 675 1300 NO 
MANI 36  M NO NO N N 0.16 0.3 66 58 11 11 680 1500 NO 
JOTHI 40  F NO NO N N 0.15 0.29 69 59 8 13.5 685 1350 NO 
AMMAL 44  F NO NO Y N 0.14 0.28 70 60 10 11.5 680 1400 NO 
VALLI 48  F NO NO N Y 0.17 0.27 64 56 9 13 685 1450 NO 
KUPPU 50  M NO NO N Y 0.16 0.26 62 54 10 12 695 1600 NO 
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